user

The Effect of SGLT2 Inhibitor Dapagliflozin on BMI in Female Adolescents with Type 1 Diabetes

被引：0
|
作者：
Roman, R. [1 ]
Valdivia, N. [2 ]
Ruiz, S. [3 ]
机构：
[1] Univ Antofagasta, Hosp Reg Antofagasta, Antofagasta, Chile
[2] Univ Antofagasta, Antofagasta, Chile
[3] Hosp Reg Antofagasta, Antofagasta, Chile
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2015年 / 84卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O15
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [41] Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy
    Siebel, Stephan
    Patel, Neha S.
    Galderisi, Alfonso
    Carria, Lori R.
    Tamborlane, William V.
    Sherr, Jennifer
    DIABETES, 2018, 67
  • [42] Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
    Fioretto, Paola
    Giaccari, Andrea
    Sesti, Giorgio
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
  • [43] Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
    Paola Fioretto
    Andrea Giaccari
    Giorgio Sesti
    Cardiovascular Diabetology, 14
  • [44] SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
    Scheen, Andre J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 818 - 820
  • [45] Systemic proteomic and metabolomic signature of the SGLT2 inhibitor dapagliflozin
    Billing, Anja
    Kim, Young-Chul
    Vallon, Volker
    Rinschen, Markus
    FASEB JOURNAL, 2022, 36
  • [46] Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
    Sands, Arthur T.
    Zambrowicz, Brian P.
    Rosenstock, Julio
    Lapuerta, Pablo
    Bode, Bruce W.
    Garg, Satish K.
    Buse, John B.
    Banks, Phillip
    Heptulla, Rubina
    Rendell, Marc
    Cefalu, William T.
    Strumph, Paul
    DIABETES CARE, 2015, 38 (07) : 1181 - 1188
  • [47] Bexagliflozin (Brenzavvy) - A Fifth SGLT2 Inhibitor for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1683): : 130 - 132
  • [48] The metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes
    Herring, R.
    Shojaee-Moradie, F.
    Garesse, R.
    Stevenage, M.
    Jackson, N.
    Lucy, C.
    Fielding, B. A.
    Umpleby, A.
    Russell-Jones, D. L.
    Davies, M.
    DIABETOLOGIA, 2019, 62 : S124 - S124
  • [49] Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes
    Herring, Roselle A.
    Shojaee-Moradie, Fariba
    Garesse, Robert
    Stevenage, Mary
    Jackson, Nicola
    Fielding, Barbara A.
    Mendis, Agampodi
    Johnsen, Sigurd
    Umpleby, A. Margot
    Davies, Melanie
    Russell-Jones, David L.
    DIABETES CARE, 2020, 43 (09) : 2128 - 2136
  • [50] Is an SGLT2 inhibitor right for your patient with type 2 diabetes?
    Lisenby, Katelin M.
    Meyer, Allison
    Slater, Nicole A.
    JOURNAL OF FAMILY PRACTICE, 2016, 65 (09): : 587 - 593
12345